Caremo Honored as "2023 Most Competitive Pharmaceutical Service Enterprise in China"

On November 18, at The 40th China Pharmaceutical Industry lnformation Annual Conference 2023, the "Top 100 China Pharmaceutical Industry Conference 2022 " has just concluded. The conference unveiled a series of heavyweight lists of the pharmaceutical industry, including the "Top 100 China Pharmaceutical Industry 2022", and the "Most Competitive Pharmaceutical Service Enterprise of China 2023" list was launched for the first time. Caremo was successfully selected by its excellent R&D strength and extensive customer recognition.

November 17 – The 2023 China Pharmaceutical Industry Development Congress opened in Beijing, integrating the 40th National Pharmaceutical Industry Information Annual Conference as a key component. Centered on the theme "Converging Strength for Development, Fortifying the Foundation of Health", the event aimed to foster a high-level collaboration platform for the pharmaceutical industry, driving innovation, inclusivity, and win-win growth within China’s pharmaceutical ecosystem, thereby contributing to global health initiatives.

As a "bellwether of China’s pharmaceutical industry", the "Top 100 Chinese Pharmaceutical Enterprises" rankings, issued by the National Pharmaceutical Industry Information Center, highlight exemplary enterprises and guide industry trends. This year, the center evaluated candidates across four dimensions—talent, technology, service, market performance, and strategic development—through data-driven analysis and rigorous review, culminating in six authoritative rankings. Among these, the debut "2023 Most Competitive Pharmaceutical Service Enterprises" list recognized Caremo’s exceptional contributions.

Driven by its mission—"Born for Health, Empowered for Innovation"—Caremo integrates core technologies to bridge innovative and generic drug development, employing a dual-drive strategy of R&D and industrialization. The company delivers customized solutions tailored to diverse client needs, aligning research innovation with industrial goals.

This honor affirms Caremo’s technical expertise, professional excellence, and innovative capabilities, while inspiring further progress. Moving forward, Caremo will collaborate with global partners across the entire R&D value chain—from target validation to commercialization—through flexible models that address differentiated demands. The company is committed to building a comprehensive, end-to-end drug discovery and production service platform, offering full-spectrum technological and industrial support to empower global biopharmaceutical innovation.